Fulcrum Therapeutics (FULC) Competitors $3.26 +0.05 (+1.56%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FULC vs. BLUE, KZR, SGMO, ORTX, ERAS, RLAY, IMNM, PHVS, ANNX, and ABUSShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include bluebird bio (BLUE), Kezar Life Sciences (KZR), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Erasca (ERAS), Relay Therapeutics (RLAY), Immunome (IMNM), Pharvaris (PHVS), Annexon (ANNX), and Arbutus Biopharma (ABUS). These companies are all part of the "medical" sector. Fulcrum Therapeutics vs. bluebird bio Kezar Life Sciences Sangamo Therapeutics Orchard Therapeutics Erasca Relay Therapeutics Immunome Pharvaris Annexon Arbutus Biopharma Fulcrum Therapeutics (NASDAQ:FULC) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Does the media prefer FULC or BLUE? In the previous week, Fulcrum Therapeutics had 1 more articles in the media than bluebird bio. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for bluebird bio. Fulcrum Therapeutics' average media sentiment score of 1.56 beat bluebird bio's score of 0.68 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive bluebird bio 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate FULC or BLUE? Fulcrum Therapeutics presently has a consensus target price of $9.33, indicating a potential upside of 186.30%. bluebird bio has a consensus target price of $4.63, indicating a potential upside of 900.72%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts clearly believe bluebird bio is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20bluebird bio 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility & risk, FULC or BLUE? Fulcrum Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Is FULC or BLUE more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -567.29%. Fulcrum Therapeutics' return on equity of -8.28% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -8.28% -7.61% bluebird bio -567.29%-207.25%-51.70% Do insiders and institutionals hold more shares of FULC or BLUE? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 1.4% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, FULC or BLUE? Fulcrum Therapeutics has higher earnings, but lower revenue than bluebird bio. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$2.81M72.39-$97.33M-$0.35-9.31bluebird bio$29.50M3.04-$211.91M-$2.22-0.21 Does the MarketBeat Community prefer FULC or BLUE? bluebird bio received 940 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 71.39% of users gave bluebird bio an outperform vote while only 62.03% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9862.03% Underperform Votes6037.97% bluebird bioOutperform Votes103871.39% Underperform Votes41628.61% SummaryFulcrum Therapeutics beats bluebird bio on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.42M$6.78B$5.09B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-9.3112.64135.8816.71Price / Sales72.39270.581,688.5176.32Price / CashN/A46.0937.1933.56Price / Book0.865.274.614.98Net Income-$97.33M$152.08M$116.08M$224.69M7 Day Performance0.62%-2.23%-0.97%-0.51%1 Month Performance-14.66%14.00%5.32%3.32%1 Year Performance-16.20%36.66%33.75%25.51% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics3.5518 of 5 stars$3.26+1.6%$9.33+186.3%-16.2%$203.42M$2.81M-9.31100Positive NewsBLUEbluebird bio3.0077 of 5 stars$0.46flat$4.63+900.7%-86.7%$89.78M$29.50M-0.21323Analyst ForecastKZRKezar Life Sciences4.0169 of 5 stars$7.09-1.7%$45.00+534.7%-16.0%$51.76M$7M-0.5260Upcoming EarningsStock SplitSGMOSangamo Therapeutics2.0293 of 5 stars$1.74-7.4%$2.67+53.3%+278.3%$362.31M$12.28M-1.26480Upcoming EarningsORTXOrchard TherapeuticsN/A$16.70flatN/AN/A$380.09M$22.66M-17.77166ERASErasca2.0255 of 5 stars$2.87+5.5%$6.10+112.5%+18.6%$810.79MN/A-3.12126RLAYRelay Therapeutics3.3298 of 5 stars$5.85+0.2%$21.11+260.9%-22.2%$783.26M$25.55M-2.32304Upcoming EarningsIMNMImmunome2.2349 of 5 stars$12.81+10.5%$29.00+126.4%+46.4%$769.24M$14.02M-1.6740Gap UpPHVSPharvaris2.0121 of 5 stars$23.93-0.9%$33.60+40.4%+29.5%$761.93MN/A-9.2830Upcoming EarningsANNXAnnexon1.3979 of 5 stars$7.09-2.6%$15.80+122.8%+173.7%$749.06MN/A-5.7660Upcoming EarningsABUSArbutus Biopharma1.5365 of 5 stars$3.87-2.3%$5.25+35.7%+101.6%$730.58M$18.14M-8.6073Upcoming Earnings Related Companies and Tools Related Companies BLUE Competitors KZR Competitors SGMO Competitors ORTX Competitors ERAS Competitors RLAY Competitors IMNM Competitors PHVS Competitors ANNX Competitors ABUS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FULC) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
